Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067974 · ClinicalTrials.gov registry record · Early Phase 1
Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study
A Early Phase 1 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03067974 is a Early Phase 1 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 10 participants.
The verdict
NCT03067974, a Early Phase 1 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the feasibility of intranasal ketamine for adequate sedation of children undergoing minor procedures in the Emergency Department. An intranasal dose of 10mg/kg will be used in patients requiring procedural sedation. The investigators hypothesize that this dose of intranasal ketamine will be able to provide adequate sedation and analgesia for the physician to successfully complete the planned diagnostic or therapeutic intervention (Pediatr Emer Care 2012;28: 767-70). The primary endpoint will be successful sedation, as defined by the ability to complete the planned procedure without rescue medication, which includes re-dosing of the same medication.
Interventions
- DRUG Ketamine Hcl 100Mg/Ml Inj
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2019-01-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03067974
The ClinicalTrials.gov registry entry for NCT03067974 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine Hcl 100Mg/Ml Inj is the first listed.
NCT03067974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03067974 about?
NCT03067974 is a clinical study titled "Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study". The purpose of this study is to evaluate the feasibility of intranasal ketamine for adequate sedation of children undergoing minor procedures in the Emergency Department. An intranasal dose of 10mg/kg will be used in patients requiring procedural sedation. The investigators hypothesize that this dos...
What is the current status of trial NCT03067974?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2017-09-21. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT03067974?
The interventions under investigation include: Ketamine Hcl 100Mg/Ml Inj (DRUG).
Who is sponsoring clinical trial NCT03067974?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.